| Literature DB >> 28293641 |
Marisol Rivera-Huerta1, Vania Lorena Lizárraga-Grimes1, Ibrahim Guillermo Castro-Torres2, Mabel Tinoco-Méndez1, Lucía Macías-Rosales1, Francisco Sánchez-Bartéz1, Graciela Guadalupe Tapia-Pérez3, Laura Romero-Romero4, María Isabel Gracia-Mora1.
Abstract
Inulin-type fructans are polymers of fructose molecules and are known for their capacity to enhance absorption of calcium and magnesium, to modulate gut microbiota and energy metabolism, and to improve glycemia. We evaluated and compared the effects of Chicory inulin "Synergy 1®" and inulin from Mexican agave "Metlin®" in two experimental models of colon cancer and bone calcium metabolism in mice and rats. Inulins inhibited the development of dextran sulfate sodium-induced colitis and colon cancer in mice; these fructans reduced the concentration of tumor necrosis factor alpha and prevented the formation of intestinal polyps, villous atrophy, and lymphoid hyperplasia. On the other hand, inulin treatments significantly increased bone densitometry (femur and vertebra) in ovariectomized rats without altering the concentration of many serum biochemical parameters and urinary parameters. Histopathology results were compared between different experimental groups. There were no apparent histological changes in rats treated with inulins and a mixture of inulins-isoflavones. Our results showed that inulin-type fructans have health-promoting properties related to enhanced calcium absorption, potential anticancer properties, and anti-inflammatory effects. The use of inulin as a prebiotic can improve health and prevent development of chronic diseases such as cancer and osteoporosis.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28293641 PMCID: PMC5331302 DOI: 10.1155/2017/9758982
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Experimental design of colon cancer model.
| Number | Experimental group | Treatment |
|---|---|---|
| 1 | Synergy 1-preinduction | 1 month with inulin treatment/AOM·DSS/8 months without inulin treatment |
| 2 | Metlin-preinduction | |
|
| ||
| 3 | Synergy 1-pre- and postinduction | 1 month with inulin treatment/AOM·DSS/8 months with inulin treatment |
| 4 | Metlin-pre- and postinduction | |
|
| ||
| 5 | Synergy 1-postinduction | AOM·DSS/9 months with inulins treatment |
| 6 | Metlin-postinduction | |
|
| ||
| 7 | Control | Administration of AOM·DSS without inulins treatment |
Experimental design of calcium metabolism.
| Number | Experimental group | Treatment |
|---|---|---|
| 1 | Metlin | Inulins were administered at doses of 385 mg/day/rat. Inulins were dissolved in water and the rats had free access to water and normal diet |
| 2 | Synergy 1 | |
|
| ||
| 3 | Isoflavones | Isoflavones were administered at doses of 33.5 mg/day/rat at the same conditions as that of the inulins |
|
| ||
| 4 | Metlin + isoflavones | A mixture of inulins and isoflavones was administered under doses indicated above |
| 5 | Synergy 1 + isoflavones | |
|
| ||
| 6 | Without inulins | Oophorectomized experimental group without inulins treatments |
|
| ||
| 7 | Without inulins | Experimental group not oophorectomized without inulins treatment |
All the rats of experimental groups 1–6 were oophorectomized and only the experimental group 7 had rats without oophorectomy.
Figure 1Histopathological studies in intestinal tissues of mice. Inulins treatments diminished the number of intestinal polyps (indicated by black arrows) compared with control group, which showed damage in intestinal mucosa. Samples were analyzed in three different times of treatment: (a) three months, (b) six months, and (c) nine months. (1) Synergy 1-preinduction. (2) Metlin-preinduction. (3) Synergy 1-pre- and postinduction. (4) Metlin- pre- and postinduction. (5) Synergy 1-postinduction. (6) Metlin-postinduction. (7) Control.
Figure 2TNFα and IL-10 concentration in intestinal samples. Values are presented as means ± SE using 5 data of TNFα and IL-10 concentration. Values indicate significant differences (p < 0.05) between groups treated with fructans versus cancer-induced group. Time 1, seven months. Time 2, nine months.
Figure 3Histology in rats with and without oophorectomy. Vaginal smear from not oophorectomized animal. (a) Anuclear squamae are seen. Papanicolaou stain ×40. (b) and (c) Diff-Quik stain. (d) Parabasal epithelial cells are seen in vaginal smear from an oophorectomized rat, Papanicolaou stain ×40. (e) and (f) Diff-Quik stain.
| Biochemical parameter | Normal data | Experimental groups | ||||||
|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | ||
| AST | 114.5 ± 25.4 | 174 ± 5.4a | 178.5 ± 5.4a | 183 ± 5.4a | 182 ± 5.4a | 181 ± 5.4a | 166.3 ± 5.4a | 172 ± 5.4a |
| ALT | 58.5 ± 10.2 | 51.2 ± 1.8ab | 54.6 ± 1.8b | 52.7 ± 1.8ab | 54.3 ± 1.8b | 53.9 ± 1.8ab | 47.1 ± 1.8a | 51 ± 1.8ab |
| FAS | 389.7 ± 49.3 | 349 ± 20.53a | 350.2 ± 20.53a | 338.8 ± 20.53a | 363.4 ± 20.53a | 379 ± 20.53a | 359.6 ± 20.53a | 303.7 ± 20.53a |
| Glucose | 7.9 ± 0.8 | 7.8 ± 0.26a | 7.7 ± 0.26a | 7.5 ± 0.26a | 7.4 ± 0.26a | 7.3 ± 0.26a | 6.9 ± 0.26a | 7.1 ± 0.26a |
| Cholesterol | 2.0 ± 0.5 | 2 ± 0.08ab | 1.83 ± 0.08ab | 2 ± 0.08ab | 2 ± 0.08ab | 2.2 ± 0.08b | 1.9 ± 0.08ab | 1.78 ± 0.08a |
| Triglycerides | 0.66 ± 0.16 | 0.9 ± 0.1ab | 0.61 ± 0.1a | 0.72 ± 0.1ab | 0.62 ± 0.1ab | 0.75 ± 0.1ab | 0.82 ± 0.1ab | 1.15 ± 0.1b |
| Creatinine | 50.7 ± 13.0 | 68.4 ± 2.2ab | 68.5 ± 2.2ab | 70.4 ± 2.2bd | 62 ± 2.2abc | 70 ± 2.2bcd | 64.3 ± 2.2ab | 61.2 ± 2.2a |
| Phosphorus | 1.54 ± 0.26 | 2.16 ± 0.06a | 2.1 ± 0.06a | 1.85 ± 0.06a | 2.06 ± 0.06a | 2.03 ± 0.06a | 1.94 ± 0.06a | 1.98 ± 0.06a |
| Calcium | 2.80 ± 0.03 | 2.66 ± 0.05b | 2.57 ± 0.05ab | 2.50 ± 0.05ab | 2.58 ± 0.05ab | 2.47 ± 0.05ab | 2.34 ± 0.05a | 2.57 ± 0.05ab |
|
| 4,878.80 ± 437.58 | 4,348 ± 342.13a | 4,139 ± 342.13a | 4,157 ± 342.13a | 3,979 ± 342.13a | 4,260 ± 342.13a | 4,069 ± 342.13a | 3,019 ± 342.13b |
|
| 1.43 ± 0.082 | 1.48 ± 0.19a | 1.60 ± 0.19a | 1.80 ± 0.19a | 1.32 ± 0.19ac | 1.93 ± 0.19ab | 1.83 ± 0.19a | 1.61 ± 0.19a |
Biochemical parameter in urine. Others parameters were analyzed in blood. AST, ALT, and FAS are expressed in IU/L, and glucose, cholesterol, triglycerides, phosphorus, and calcium are expressed in mmol/L and creatinine in μmol/L. Different letters indicate significant differences (p < 0.05) between all experimental groups. Experimental groups, 1, Metlin; 2, Synergy 1; 3, isoflavones; 4, Metlin + isoflavones; 5, Synergy 1 + isoflavones; 6, oophorectomized rats without inulins treatment; 7, not oophorectomized rats without inulins treatment.
| Bone | Experimental groups | ||||||
|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | |
| Femur | 0.231 ± .003abc | 0.239 ± .003bdc | 0.234 ± .003abdc | 0.243 ± .003bd | 0.236 ± .003bdc | 0.225 ± .003ac | 0.233 ± .003abc |
| Vertebra | 0.212 ± .004bd | 0.205 ± .004abe | 0.207 ± .004abe | 0.220 ± .004bdf | 0.195 ± .004ace | 0.195 ± .004ae | 0.205 ± .004abe |
Different letters indicate significant differences (p < 0.05) between all experimental groups. Experimental groups, 1, Metlin; 2, Synergy 1; 3, isoflavones; 4, Metlin + isoflavones; 5, Synergy 1 + isoflavones; 6, oophorectomized rats without inulins treatment; 7, not oophorectomized rats without inulins treatment.